within Pharmacolibrary.Drugs.ATC.D;

model D05AX07
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00023666666666666665,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.391,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D05AX07</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tapinarof is an aryl hydrocarbon receptor (AhR) agonist indicated for the topical treatment of plaque psoriasis in adults. It is a non-steroidal, small-molecule therapeutic, and is currently approved for use as a topical cream.</p><h4>Pharmacokinetics</h4><p>Reported in healthy adult subjects after topical administration.</p><h4>References</h4><ol><li><p>Bissonnette, R, et al., &amp; Armstrong, A (2021). Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. <i>Journal of the American Academy of Dermatology</i> 84(4) 1059–1067. DOI:<a href=\"https://doi.org/10.1016/j.jaad.2020.10.085\">10.1016/j.jaad.2020.10.085</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33157177/\">https://pubmed.ncbi.nlm.nih.gov/33157177</a></p></li><li><p>Silverberg, JI, et al., &amp; McHale, KA (2024). Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review. <i>The Journal of allergy and clinical immunology</i> 154(1) 1–10. DOI:<a href=\"https://doi.org/10.1016/j.jaci.2023.12.013\">10.1016/j.jaci.2023.12.013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38154665/\">https://pubmed.ncbi.nlm.nih.gov/38154665</a></p></li><li><p>Lo, A, et al., &amp; Feldman, SR (2024). Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients. <i>Expert opinion on drug metabolism &amp; toxicology</i> 20(4) 235–248. DOI:<a href=\"https://doi.org/10.1080/17425255.2024.2337749\">10.1080/17425255.2024.2337749</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38553411/\">https://pubmed.ncbi.nlm.nih.gov/38553411</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D05AX07;
